Bone mineral density in Turner syndrome: relation to GH treatment and estrogen treatment.
The bone mineral density (BMD) of the second metacarpal bone of the left hand was measured in 57 patients with Turner syndrome by the digital image processing (DIP) method to study the relations between the treatment regimen and their bone mineral density. BMD SD score in the patients who had started the GH treatment before 10 years old was within +/-2SD of the standard before 14 years, but the score decreased to below -2SD after 14 years. In the patients who had started GH treatment after 10 years old, BMD score were significantly lower than -2SD, although there was tendency to increased. In the patients who had estrogen after 15 years old, BMD did not increase with GH alone and slowly increased after estrogen replacement. In the other two patients who had started sex steroid hormone replacement treatment before 15 years old, BMD maintained +/-2SD. In patients who received combined GH and LH-RH analog treatment, their BMD score did not increase during LH-RH analog treatment. It slowly increased but was still below -3SD after stop of LH-RH analog and start of estrogen treatment. In Turner syndrome, GH may play a role in maintaining prepubertal BMD levels [4], and estrogen plays an important role in pubertal BMD increment. It is recommended that estrogen treatment is started before 15 years of age for maintenance of normal BMD level.
Sato
N
N
Department of Endocrinology and Metabolism, National Children's Medical Research Center, Tokyo, Japan.
Nimura
A
A
Horikawa
R
R
Katumata
N
N
Tanae
A
A
Tanaka
T
T
D000293:Adolescent; D000328:Adult; D015519:Bone Density / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D015914:Estrogen Replacement Therapy; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008137:Longitudinal Studies; D008663:Metacarpus / Q000187:drug effects / Q000378:metabolism; D014424:Turner Syndrome / Q000188:drug therapy* / Q000378:metabolism*
D013006:Growth Hormone